Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Fernandez HF, et al. Biol Blood Marrow Transplant. 2002;8(9):486-92. doi: 10.1053/bbmt.2002.v8.pm12374453. Biol Blood Marrow Transplant. 2002. PMID: 12374453 Free article. Clinical Trial.
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Bahlis NJ, et al. Among authors: fernandez hf. Clin Cancer Res. 2002 Dec;8(12):3658-68. Clin Cancer Res. 2002. PMID: 12473574 Clinical Trial.
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.
Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Pidala J, et al. Among authors: fernandez hf. Int J Hematol. 2011 Feb;93(2):206-212. doi: 10.1007/s12185-010-0747-x. Epub 2011 Jan 19. Int J Hematol. 2011. PMID: 21246311 Free PMC article.
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Cortes J, et al. Among authors: fernandez hf. Cancer. 2012 Jan 15;118(2):418-27. doi: 10.1002/cncr.26292. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717444 Free PMC article. Clinical Trial.
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Nishihori T, et al. Among authors: fernandez hf. Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26. Br J Haematol. 2012. PMID: 22449149 Free PMC article. Clinical Trial.
104 results